While the company claimed its shot may be working, the effects weren’t conclusive nor were they correlated with a marker meant to indicate a treatment response.

Dive Brief:
Gritstone Bio on Monday said a personalized cancer vaccine it’s developing showed potential in people with colorectal tumors, but the data released by the company aren’t strong enough to prove the treatment works.
Preliminary study results suggest what Gritstone described as an “early trend” in benefit, appearing to lessen the risk of progression in participants who received the shot alongside immunotherapy and chemotherapy compared to those who didn’t.
But that finding wasn’t statistically conclusive and, importantly, a biological marker used to assess treatment response was “uninformative,” the company said. Shares in Gritstone lost nearly half of their value in Tuesday morning trading.

Posted in

Iron Will

Leave a Comment

You must be logged in to post a comment.